Daxor Corporation

254 articles with Daxor Corporation

• Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

  9/7/2021

  Daxor Corporation, the global leader in blood volume measurement technology, announces that President and Chief Executive Officer Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.

• Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021

  8/30/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2021.

• Daxor’s Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical Care

  8/4/2021

  Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data published in the journal Critical Care showing Daxor’s unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care.

• American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

  7/13/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces an expert analysis titled, “Anemia and Heart Failure: Guidance for Clinicians and Trialists'' published July 6, 2021 in the American College of Cardiology (ACC) online clinical topics section: https://www.acc.org/latest-in-cardiology/articles/2021/07/06/12/18/anemia-and-heart-failure.

• Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

  5/28/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer will present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 2, 2021 at 4:30 PM ET.

• Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

  5/13/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis. In addition, the sales team has recorded the opening of five new customer accounts utilizing BVA and reports a growing pipeline of additional acquisitions of Daxor’s BVA-100 Blood Volume Analyzer slated for Q3 2021

• Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs

  5/6/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure (ADHF) utilizing the BVA-100 blood test

• Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

  4/29/2021

  Daxor Corporation(NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in postural tachycardia syndrome (POTS) published in the Journal of the American College of Cardiology from the Vanderbilt Autonomic Dysfunction Center in Nashville, TN.

• DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE

  3/18/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will participate in the Benzinga Biotech Small Cap Conference to be held March 24th to 25th, 2021.

• Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference

  3/16/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at Maxim Group 2021 Emerging Growth Virtual Conference to be held March 17-19, 2021, 9:00 AM - 5:00 PM EST.

• DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER

  3/15/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two contract from the United States Air Force (USAF) to implement a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer

• Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 10th through a virtual format with on-demand video presentations.

• Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020

  2/26/2021

  Daxor Corporation(NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2020.

• DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)

  2/19/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been officially recognized as meeting all the requirements of ISO 13485; Medical Devices, Quality Management System Certification ensuring the consistent design, development, production, installation, and delivery for the Blood Volume Analyzer (BVA-100®) system is safe for its intended purpose.

• DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

  2/5/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2)

• New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care

  2/4/2021

  Daxor Corporation(NYSE MKT: DXR) the global leader in blood volume measurement technology, today announces new data from the University of Hawaii John A. Burns School of Medicine showing the BVA-100 blood test accurately and uniquely reflects blood volume status after massive blood transfusion, a key metric for this procedure, while traditional clinical metrics fail in 80% of the cases analyzed.

• DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT

  1/26/2021

  NEW DATA SCHEDULED FOR PRESENTATION ON DAXOR’S BVA-100 ® BLOOD TEST NEW YORK, Jan. 26, 2021

• DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR

  1/13/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new distribution agreement with L1 Enterprises, a leading provider of medical equipment and supplies to the government marketplace including the Department of Defense (DOD), Department of Veterans Affairs (

• Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference

  1/8/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference

• Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

  12/10/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major medical centers across the U.S.